Latest Financial Management News

Focus Minerals Ltd. reported record ore processing at its Three Mile Hill plant and significant progress on the Bonnie Vale Underground Mine during the December 2024 quarter, supported by a solid cash position of $16.5 million.

Hawthorn Resources has completed a pivotal Pre-Feasibility Study for its Mt Bevan Magnetite project and strategically converted its equity stake into a royalty, positioning the company for future value capture amid evolving market dynamics.

High Peak Royalties has fully repaid its US$750,000 financing facility with Macquarie Bank, removing all associated securities and guarantees. The company signals confidence in its near-term liquidity and operational funding.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

Mt Malcolm Mines NL reports a successful quarter with 122.4 ounces of gold doré produced from its Golden Crown Prospect, generating AUD$449,194 in revenue and confirming high-grade mineralisation.

Rand Mining Ltd. reported a robust December quarter with 5,369 ounces of gold produced and a significant rise in operating cash inflows, underpinned by targeted drilling and operational efficiencies.

Rey Resources Limited reported a cautious quarterly cash flow with $276,000 in cash and ongoing strategic moves in its oil and gas exploration portfolio, including the surrender of EP458 and preparations for a key 3D seismic survey on EP487.

Future Metals NL has identified a promising new mineralised zone at its Eileen Bore Prospect and continues to advance drilling at Target 2, all while implementing strategic cost reductions amid subdued PGM prices.

Citigold Corporation reports steady progress in restarting its Charters Towers Gold Project, highlighting successful test mining and ongoing exploration while preparing for large-scale production.

Farm Pride Foods has successfully recovered from Avian Influenza setbacks, improving cash flows and repaying significant debt while investing in biosecurity and production upgrades.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Quickstep Holdings reports a 21% revenue decline but a 44% EBITDA increase in Q2 FY25, driven by restructuring and strategic progress with Defence contracts.